CD1d expression in glioblastoma is a promising target for NKT cell-based cancer immunotherapy.
Hara A, Koyama-Nasu R, Takami M, Toyoda T, Aoki T, Ihara F, Kobayashi M, Hirono S, Matsutani T, Nakayama T, et al. Cancer Immunol Immunother. 2021 May; 70(5):1239-1254. Epub 2020 Oct 31.